Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8648097 | SANTEN | Pyridylaminoacetic acid compound |
Oct, 2029
(5 years from now) | |
US10774072 | SANTEN | Crystal of N-substituted sulfonamide compound |
Jun, 2035
(11 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8685986 | SANTEN | Medical composition for treatment or prophylaxis of glaucoma |
Oct, 2029
(5 years from now) | |
US11197849 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
US10702511 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
US9415038 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
USRE48183 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
US10179127 | SANTEN | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
US10765750 | SANTEN | Pharmaceutical composition containing pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) | |
US11666563 | SANTEN | Pharmaceutical preparation containing pyridyl aminoacetic acid compound |
Jul, 2039
(15 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 22, 2027 |
NCE-1 date: 2026-09-22
Market Authorisation Date: 22 September, 2022
Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients
Dosage: SOLUTION;OPHTHALMIC
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11793798 | VISIOX PHARMA | Pharmaceutical formulations comprising a pyridylaminoacetic acid compound |
Jan, 2035
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 22, 2027 |
NCE-1 date: 2026-09-22
Market Authorisation Date: 22 September, 2022
Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients
Dosage: SOLUTION;OPHTHALMIC